Image

Global Pediatric Drugs Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Pediatric Drugs Market, By Drug Type (Allergy and Respiratory Drugs, Cancer Therapies, Anti-Infectives, Cardiovascular Drugs, Gastrointestinal Drugs, Central Nervous System Drugs, Hormone Drugs, Urological Drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Pediatric Drugs Market

Market Analysis and Size

In recent years, the pediatric drugs market is anticipated to grow rapidly during the forecast period. By 2020, 5.0 million children under the age of five are anticipated to die, according to the United Nations International Children's Emergency Fund (UNICEF) 2020 Report. This would equate to 13,800 children under the age of five dying every day by 2020. Preterm birth and intrapartum complications, as well as infectious illnesses including pneumonia, diarrhoea, and malaria, continue to be the major causes of death among children under the age of five around the world. As a result, deaths among children under the age of five necessitate prompt care.

Data Bridge Market Research analyses that the pediatric drugs market was valued at USD 117.20 billion in 2021 and is expected to reach USD 300.70 billion by 2029, registering a CAGR of 12.5% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

Patients between the ages of 2 and 12 are given pediatric drugs. Pediatric therapy must be distinct from adult therapy not only due to the necessity to accommodate varied dosage regimens but also because a child's response to a drug may differ from that of an adult.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Drug Type (Allergy and Respiratory Drugs, Cancer Therapies, Anti-Infectives, Cardiovascular Drugs, Gastrointestinal Drugs, Central Nervous System Drugs, Hormone Drugs, Urological Drugs, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Zydus Cadila (India), AstraZeneca (UK), Johnson & Johnson (US), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Cipla Inc. (US), Mallinckrodt (US), Apotex Inc. (Canada), Hikma Pharmaceuticals PLC (UK), Endo International plc (Ireland)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment in the development of advanced technologies
  • Surging drug approvals and launches

Pediatric Drugs Market Dynamics

Drivers

  • Increasing prevalence of chronic disorders

The rising prevalence of chronic disorders is estimated to enhance the market's growth. Chronic disorders such as anorexia, asthma, birth defects, growth deficiencies, diabetes, cancer in children, juvenile diabetes, and attention deficit hyperactivity among others is the major factor enhancing the demand of pediatric drugs, hence, influencing the market dynamics during the forecast period of 2022-2029.

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of pediatric drugs market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aim to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

Furthermore, rising initiatives by public and private organizations to spread awareness and growing incidences of obesity among children will expand the pediatric drugs market. Additionally, changing lifestyle of people and the rising population will result in the expansion of pediatric drugs market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the pediatric drugs market growth. The presence of many measures such as the Best Pharmaceuticals for Children Act (BPCA) and the Pediatric Research Equity Act (PREA) is driving big businesses to enhance their R&D investments in pediatric drug research. Along with this, rising drug approvals and launches will further propel the market’s growth rate. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the pediatric drugs market growth during the forecast period.

Restraints/Challenges

On the other hand, the less number of study population and ethical issues in pediatric research will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the pediatric drugs market. Additionally, side effects associated with pediatric drugs including headache along with anxiety, and lack of awareness among people will act as restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This pediatric drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pediatric drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Pediatric drugs market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Pediatric Drugs Market

Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in several nations had imposed nationwide lockdowns in order to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The pediatric drugs market was hampered by the supply chain slowness.

Recent Development

  • In October 2021, the United States Food and Drug Administration (FDA) announced the approval of Rethymic which is used for treating pediatric patients suffering from congenital athymia, a rare immune disorder. Rethymic is the first thymus tissue product approved in the United States.

Global Pediatric Drugs Market Scope

The pediatric drugs market is segmented on the basis of drug type, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Drug Type

  • Allergy and Respiratory Drugs
  • Cancer Therapies
  • Anti-Infectives
  • Cardiovascular Drugs
  • Gastrointestinal Drugs
  • Central Nervous System Drugs
  • Hormone Drugs
  • Urological Drugs
  • Others

Route of Administration

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Pediatric Drugs Market Regional Analysis/Insights

The pediatric drugs market is analysed and market size insights and trends are provided by country, drug type, route of administration, end-users and distribution channel as referenced above.

The countries covered in the pediatric drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the pediatric drugs market because of the rising number of research activities in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period due to presence of generic manufacturers in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Pediatric Drugs Market Share Analysis

The pediatric drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to pediatric drugs market.

Some of the major players operating in the pediatric drugs market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (US)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Sanofi (France)
  • Pfizer Inc. (US)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Zydus Cadila (India)
  • AstraZeneca (UK)
  • Johnson & Johnson (US)
  • Bayer AG (Germany)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Bristol-Myers Squibb Company (US)
  • Eli Lilly and Company (US)
  • Cipla Inc. (US)
  • Mallinckrodt (US)
  • Apotex Inc. (Canada)
  • Hikma Pharmaceuticals PLC (UK)
  • Endo International plc (Ireland)


SKU-
Why Choose Us


Frequently Asked Questions

The market value for Pediatric Drugs Market is expected USD 300.70 billion by 2029.
The Pediatric Drugs Market is to grow at a CAGR of 12.5 % during the forecast period of 2022 to 2029
The major players operating in the Pediatric Drugs Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Zydus Cadila (India), AstraZeneca (UK), Johnson & Johnson (US), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), Merck & Co., Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Cipla Inc. (US), Mallinckrodt (US), Apotex Inc. (Canada), Hikma Pharmaceuticals PLC (UK), Endo International plc (Ireland).
The major countries covered in the Pediatric Drugs Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.